Humana exceeds Top Quartile 2027 MA Stars; affirms at least $9.00 FY2026 adjusted EPS
Humana reported exceeding its Top Quartile goal for 2027 Medicare Advantage Star Ratings, with Stars revenue PMPM 10% above peer median. The company reaffirmed its FY2026 adjusted EPS guidance of at least $9.00. Humana plans to treat some 2028 outperformance as a one-time benefit for investments and shareholder return. A virtual investor update is scheduled for December 10, 2026.
How this was made
The 30-second read
Why it matters
The reaffirmed EPS floor and star rating exceed expectations, likely prompting a positive price reaction.
Market read
Fresh guidance and star rating performance provide a material catalyst for HUM stock.
What to watch
Potential cost pressures from upcoming 2028 investments could temper upside.
Background
Humana filed an 8‑K on Oct 9, 2026 announcing its star rating results and reaffirming FY2026 EPS guidance.
Ticker impact
Humana reaffirmed FY2026 adjusted EPS of at least $9.00 and reported exceeding Top Quartile 2027 Medicare Advantage Star Ratings.
likely upside as investors price in higher earnings guidance
The new EPS floor and star rating exceed peer median, providing fresh, material information that can move the stock.
Market effects
May lift other Medicare Advantage insurers as benchmark for star rating performance.
Positive for U.S. health‑care sector.
Limited to U.S. markets; no direct global effect.
Counterpoint
If the star rating boost is viewed as a one‑time benefit, the guidance may not be sustainable.
Key entities
- companyHumana Inc.
U.S. health insurance provider.
